Appointment of Nominated Adviser and Broker

25 November 2025

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 Appointment of Nominated Adviser and Broker

Proteome Sciences (AIM:PRM), is pleased to announce that SP Angel Corporate Finance LLP has been appointed as the Company's new Nominated Adviser and sole Broker with immediate effect.

Christopher Pearce, Executive Chairman commented that:  'We are delighted to have the opportunity to work closely with the team at SP Angel and look forward to their support as we further develop Proteome Sciences.'

For further information:

AIM Rule 17 Disclosures

In accordance with AIM Rule 17 and Schedule Two (g) sub-paragraph (v) of the AIM Rules for Companies, the Company confirms that between 2001 and 2015 Roger McDowell, Non-Executive Director, was a director or partner of the following companies at the time of, or in the 12 months preceding, such company entering administration or liquidation proceedings:

-      Town Index Limited - Creditors Voluntary Liquidation in January 2001, and subsequently dissolved in 2005;

-   Wax Digital Limited (subsequently Onward Digital Ltd) - Creditors Voluntary Liquidation in 2001, and subsequently dissolved in 2015;

-      Advanced Fluid Connections plc - Appointment of Receivers in 2006, and subsequently dissolved in 2009;

-      IDMoS plc - Appointment of Administrators in April 2008 (with Administration in May 2008), and subsequently dissolved in 2009; and

-      Corsair Techinvest Ltd - Members Voluntary Solvent Liquidation in 2015.

- Ends -

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.